With this background, we thus investigated the possible role of RES in reversing the adverse effects of anti-VEGF (BEV), thereby providing an option for a combined therapy of anti-VEGF and RES in wet AMD and PDR patients. This evidence concerns the gene VEGFA and age-related macular degeneration.